Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Renal Cell 3Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Etoposide 78Carboplatin 67Cisplatin 46durvalumab 26Topotecan 26atezolizumab 20Radiotherapy 19Irinotecan 19Paclitaxel 17anlotinib 16apatinib 15Nivolumab 15Drug Therapy 12pembrolizumab 9Platinum 9toripalimab 8tislelizumab 8Gemcitabine 8Bevacizumab 8Temozolomide 7Radiosurgery 7PM 01183 7Ipilimumab 7Pemetrexed 6Docetaxel 6Albumin-Bound Paclitaxel 6olaparib 5amrubicin 5Sunitinib 5surufatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Small Cell Lung Carcinoma × vorolanib × Clear all
NCT04373369 2025-11-03

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Washington University School of Medicine

Phase 2 Terminated
11 enrolled 10 charts
Thoracic

Small Cell Lung Carcinoma

NCT03904719 2020-07-09

CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

AnewPharma

Phase 2 Unknown
30 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡